Filtros de búsqueda

Lista de obras de Ajay K Gopal

131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.

scientific article published on 30 March 2009

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

artículo científico publicado en 2005

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes

artículo científico publicado en 2012

90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution

artículo científico publicado en 2014

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

artículo científico publicado en 2009

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

artículo científico publicado en 2013

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

artículo científico publicado en 2013

A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.

artículo científico publicado en 2013

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

scientific article published on 01 November 2000

A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma

artículo científico publicado en 2015

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

artículo científico publicado en 2013

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

artículo científico publicado en 2015

Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older

artículo científico publicado en 2005

Acute Appendicitis in a Man Undergoing Therapy for Mantle Cell Lymphoma ⬇️

artículo científico publicado el 29 de marzo de 2012

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade

scientific article published on 22 June 2020

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

artículo científico publicado en 2008

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2009

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy ⬇️

artículo científico publicado el 12 de septiembre de 2011

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

artículo científico publicado en 2015

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications

artículo científico publicado en 2017

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

artículo científico publicado en 2011

Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model ⬇️

artículo científico publicado el 7 de marzo de 2013

Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model

artículo científico publicado en 2014

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment

artículo científico publicado en 2015

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

artículo científico publicado en 2015

Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial

scientific article published on 14 September 2018

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma

artículo científico publicado en 2016

Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.

artículo científico publicado en 2015

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

scientific article published on 07 January 2019

Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

artículo científico publicado en 2014

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma ⬇️

artículo científico publicado el 18 de mayo de 2012

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

scientific article published on 24 February 2014

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.

scientific article published on 26 April 2016

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results ⬇️

artículo científico publicado el 3 de febrero de 2012

CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies.

artículo científico publicado en 2017

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

artículo científico publicado en 2013

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood a

scientific article published on 07 August 2017

Clinical applications of anti-CD20 antibodies.

artículo científico publicado en 1999

Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms

artículo científico publicado en 2012

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma

artículo científico publicado en 2016

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

artículo científico publicado en 2016

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models

artículo científico publicado en 2015

Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma

scientific article published on 01 December 2004

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

artículo científico publicado en 2010

Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines

artículo científico publicado en 2007

Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium

artículo científico publicado en 2010

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

artículo científico publicado en 2016

Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.

artículo científico publicado en 2001

Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.

artículo científico publicado en 2007

Evaluating paravalvular leak after TAVR

scientific article published on 02 September 2014

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

artículo científico publicado en 2014

Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies

artículo científico publicado en 2008

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

artículo científico publicado en 2020

High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.

artículo científico publicado en 2004

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma

artículo científico publicado en 2015

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

artículo científico publicado en 2007

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

artículo científico publicado en 2002

High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.

artículo científico publicado en 2008

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

artículo científico publicado en 2003

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation

artículo científico publicado en 2011

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

artículo científico publicado en 2018

Idelalisib for the treatment of non-Hodgkin lymphoma.

artículo científico publicado en 2016

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

artículo científico publicado en 2017

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy

artículo científico publicado en 2006

In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation

scientific article published on 13 April 2011

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

artículo científico publicado en 2017

Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry

scientific article published on 01 October 1999

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma

scientific article published on 03 July 2018

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation

artículo científico publicado en 2014

Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM™) in de novo coronary stenoses

artículo científico publicado en 2017

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma

artículo científico publicado en 2015

Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation

artículo científico publicado en 2017

Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation ⬇️

artículo científico publicado el 5 de julio de 2011

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.

artículo científico publicado en 2016

Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose

scientific article published on 15 April 2008

Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma

artículo científico publicado en 2014

New targeted therapies for indolent B-cell malignancies in older patients.

artículo científico

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients

artículo científico publicado en 2014

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy

scientific article published on 21 May 2019

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

artículo científico publicado en 2014

Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy

artículo científico publicado en 2017

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

artículo científico publicado en 2014

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

scientific article published on 02 January 2019

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

artículo científico publicado en 2017

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

artículo científico publicado en 2012

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy

artículo científico publicado en 2017

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.

artículo científico publicado en 2016

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

artículo científico publicado en 2016

Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

artículo científico publicado en 2009

Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma

artículo científico publicado en 2011

Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy.

artículo científico publicado en 2000

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.

artículo científico publicado en 2014

Radioimmunoconjugates in hematopoietic stem cell transplantation.

artículo científico publicado en 2009

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

artículo científico publicado en 2015

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome

artículo científico publicado en 2014

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

artículo científico publicado en 2016

Relapsed mantle cell lymphoma presenting as "sister Mary joseph nodule".

artículo científico publicado en 2010

Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma

artículo científico publicado en 2017

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

artículo científico publicado en 2014

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

artículo científico publicado en 2008

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

artículo científico publicado en 2012

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review

artículo científico publicado en 2017

Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.

artículo científico publicado en 2001

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

artículo científico publicado en 2017

The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells

artículo científico publicado en 2012

The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.

artículo científico publicado en 2007

The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation

artículo científico publicado en 2007

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

artículo científico publicado en 2020

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

artículo científico publicado en 2017

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma

artículo científico publicado en 2018

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

artículo científico publicado en 2014

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation ⬇️

artículo científico publicado el 28 de marzo de 2012

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

artículo científico publicado en 2015

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

artículo científico publicado en 2017

What is the role of transplantation for indolent lymphoma?

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

scientific article published on 03 October 2019

⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda